These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 34414701)
1. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer. Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701 [TBL] [Abstract][Full Text] [Related]
2. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881 [TBL] [Abstract][Full Text] [Related]
3. Eight-lncRNA signature of cervical cancer were identified by integrating DNA methylation, copy number variation and transcriptome data. Zhong Q; Lu M; Yuan W; Cui Y; Ouyang H; Fan Y; Wang Z; Wu C; Qiao J; Hang J J Transl Med; 2021 Feb; 19(1):58. PubMed ID: 33557879 [TBL] [Abstract][Full Text] [Related]
4. Bioinformatics Analysis of the Expression of Key Long Intergenic Non-Protein Coding RNA Genes in Bladder Cancer. Lin YZ; Wu YP; Ke ZB; Cai H; Chen DN; Chen SH; Li XD; Lin TT; Huang JB; Zheng QS; Xue XY; Xu N; Wei Y Med Sci Monit; 2020 Apr; 26():e920504. PubMed ID: 32277695 [TBL] [Abstract][Full Text] [Related]
5. Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma. Li M; Long S; Hu J; Wang Z; Geng C; Ou S Aging (Albany NY); 2019 Nov; 11(21):9405-9423. PubMed ID: 31692451 [TBL] [Abstract][Full Text] [Related]
6. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. Bao Z; Zhang W; Dong D Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759 [TBL] [Abstract][Full Text] [Related]
7. RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update. He RQ; Huang ZG; Li TY; Wei YP; Chen G; Lin XG; Wang QY Cell Physiol Biochem; 2018; 50(4):1474-1495. PubMed ID: 30359990 [TBL] [Abstract][Full Text] [Related]
8. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs. Zhao Q; Fan C BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053 [TBL] [Abstract][Full Text] [Related]
9. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer. Tan Z; Fu S; Zuo J; Wang J; Wang H Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832 [TBL] [Abstract][Full Text] [Related]
10. Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation. Zheng M; Hu Y; Gou R; Nie X; Li X; Liu J; Lin B Biomed Pharmacother; 2020 Apr; 124():109810. PubMed ID: 32000042 [TBL] [Abstract][Full Text] [Related]
11. A six-long non-coding RNA signature predicts prognosis in melanoma patients. Yang S; Xu J; Zeng X Int J Oncol; 2018 Apr; 52(4):1178-1188. PubMed ID: 29436619 [TBL] [Abstract][Full Text] [Related]
12. Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study. Ye Z; Liu C; Wu S; Jin X; Lin H; Wang T; Zheng Q; Guo Z Medicine (Baltimore); 2024 May; 103(18):e38005. PubMed ID: 38701267 [TBL] [Abstract][Full Text] [Related]
13. Novel Long Non-coding RNA Markers for Prognostic Prediction of Patients with Bladder Cancer. Li WX; Zhang YL Chin Med Sci J; 2020 Sep; 35(3):239-247. PubMed ID: 32972501 [TBL] [Abstract][Full Text] [Related]
14. Copy number variations primed lncRNAs deregulation contribute to poor prognosis in colorectal cancer. Liu H; Gu X; Wang G; Huang Y; Ju S; Huang J; Wang X Aging (Albany NY); 2019 Aug; 11(16):6089-6108. PubMed ID: 31442207 [TBL] [Abstract][Full Text] [Related]
15. Dysregulated ceRNA network modulated by copy number variation-driven lncRNAs in breast cancer: A comprehensive analysis. Zhu X; Song J; Wang M; Wang X; Lv L J Gene Med; 2023 Mar; 25(3):e3471. PubMed ID: 36525372 [TBL] [Abstract][Full Text] [Related]
16. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer. Gao X; Cai J Front Genet; 2022; 13():865204. PubMed ID: 35571063 [No Abstract] [Full Text] [Related]
17. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Lu H; Wu J; Liang L; Wang X; Cai H Front Immunol; 2022; 13():803355. PubMed ID: 35154117 [TBL] [Abstract][Full Text] [Related]
18. Identification of a Prognostic Colorectal Cancer Model Including LncRNA FOXP4-AS1 and LncRNA BBOX1-AS1 Based on Bioinformatics Analysis. Shi ZL; Zhou GQ; Guo J; Yang XL; Yu C; Shen CL; Zhu XG Cancer Biother Radiopharm; 2022 Dec; 37(10):893-906. PubMed ID: 33481661 [No Abstract] [Full Text] [Related]
19. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H Front Immunol; 2022; 13():916800. PubMed ID: 35860239 [TBL] [Abstract][Full Text] [Related]
20. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs. Yang X; Zhang Y; Liu J; Feng Y Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]